Jessica Wenthe
Uppsala, C, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Safety of intratumoral immunostimulatory LOAd703 gene therapy combined with chemotherapy in patients with advanced cancer.
Journal: Immuno-oncology technology
Published: March 11, 2026
Tumor Microenvironment Gene Engineering with LOAd703 in Patients with Solid Malignancies: LOKON002 Phase I/IIb Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 17, 2025
LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study.
Journal: The Lancet. Oncology
Published: September 19, 2023
CD40 stimulation via CD40 ligand enhances adenovirus-mediated tumour immunogenicity including 'find-me', 'eat-me', and 'kill-me' signalling.
Journal: Journal of cellular and molecular medicine
Published: July 25, 2023
Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models.
Journal: Journal of translational medicine
Published: May 11, 2023
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition.
Journal: Molecular therapy oncolytics
Published: September 03, 2021
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.
Journal: Cancer immunology, immunotherapy : CII
Published: October 08, 2020
Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes.
Journal: Molecular therapy oncolytics
Published: September 10, 2020
Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.
Journal: Cancer gene therapy
Published: June 11, 2020
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.
Journal: Cancer gene therapy
Published: March 02, 2020
IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: May 22, 2018
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 07, 2018
Last Updated: 09/26/2026